Cargando…

Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study

BACKGROUND: Cancer and factor V Leiden mutation are both risk factors for venous thromboembolism (VTE). Cancer critically increases the thrombotic risk whereas Factor V Leiden is the most common pro-thrombotic mutation. The impact of the factor V Leiden on the risk of VTE in cancer patients remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Heraudeau, Adeline, Delluc, Aurélien, Le Henaff, Mickaël, Lacut, Karine, Leroyer, Christophe, Desrues, Benoit, Couturaud, Francis, Tromeur, Cécile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959061/
https://www.ncbi.nlm.nih.gov/pubmed/29775482
http://dx.doi.org/10.1371/journal.pone.0194973
_version_ 1783324323603283968
author Heraudeau, Adeline
Delluc, Aurélien
Le Henaff, Mickaël
Lacut, Karine
Leroyer, Christophe
Desrues, Benoit
Couturaud, Francis
Tromeur, Cécile
author_facet Heraudeau, Adeline
Delluc, Aurélien
Le Henaff, Mickaël
Lacut, Karine
Leroyer, Christophe
Desrues, Benoit
Couturaud, Francis
Tromeur, Cécile
author_sort Heraudeau, Adeline
collection PubMed
description BACKGROUND: Cancer and factor V Leiden mutation are both risk factors for venous thromboembolism (VTE). Cancer critically increases the thrombotic risk whereas Factor V Leiden is the most common pro-thrombotic mutation. The impact of the factor V Leiden on the risk of VTE in cancer patients remains uncertain. OBJECTIVE: To assess the impact of factor V Leiden mutation in cancer-associated thrombosis. METHODS: The EDITH hospital-based case-control study enrolled 182 patients with cancer and VTE as well as 182 control patients with cancer, matched for gender, age and cancer location, between 2000 and 2012, in the University Hospital of Brest. All cases and controls were genotyped for the factor V Leiden mutation and interviewed with a standardized questionnaire. RESULTS: Twenty one of 182 (11.5%) patients with cancer-associated thrombosis carried the factor V Leiden mutation and 4 of 182 (2.2%) controls with cancer but no venous thrombosis. In multivariate analysis including cancer stage and family history of VTE, cancer patients with factor V Leiden mutation had a seven-fold increased risk of venous thromboembolism (adjusted odds ratio [OR], 7.04; 95% CI, 2.01–24.63). CONCLUSION: The pro-thrombotic Factor V Leiden mutation was found to be an independent additional risk factor for venous thromboembolism in cancer patients and might therefore be considered in the individual thrombotic risk assessment.
format Online
Article
Text
id pubmed-5959061
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59590612018-05-31 Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study Heraudeau, Adeline Delluc, Aurélien Le Henaff, Mickaël Lacut, Karine Leroyer, Christophe Desrues, Benoit Couturaud, Francis Tromeur, Cécile PLoS One Research Article BACKGROUND: Cancer and factor V Leiden mutation are both risk factors for venous thromboembolism (VTE). Cancer critically increases the thrombotic risk whereas Factor V Leiden is the most common pro-thrombotic mutation. The impact of the factor V Leiden on the risk of VTE in cancer patients remains uncertain. OBJECTIVE: To assess the impact of factor V Leiden mutation in cancer-associated thrombosis. METHODS: The EDITH hospital-based case-control study enrolled 182 patients with cancer and VTE as well as 182 control patients with cancer, matched for gender, age and cancer location, between 2000 and 2012, in the University Hospital of Brest. All cases and controls were genotyped for the factor V Leiden mutation and interviewed with a standardized questionnaire. RESULTS: Twenty one of 182 (11.5%) patients with cancer-associated thrombosis carried the factor V Leiden mutation and 4 of 182 (2.2%) controls with cancer but no venous thrombosis. In multivariate analysis including cancer stage and family history of VTE, cancer patients with factor V Leiden mutation had a seven-fold increased risk of venous thromboembolism (adjusted odds ratio [OR], 7.04; 95% CI, 2.01–24.63). CONCLUSION: The pro-thrombotic Factor V Leiden mutation was found to be an independent additional risk factor for venous thromboembolism in cancer patients and might therefore be considered in the individual thrombotic risk assessment. Public Library of Science 2018-05-18 /pmc/articles/PMC5959061/ /pubmed/29775482 http://dx.doi.org/10.1371/journal.pone.0194973 Text en © 2018 Heraudeau et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Heraudeau, Adeline
Delluc, Aurélien
Le Henaff, Mickaël
Lacut, Karine
Leroyer, Christophe
Desrues, Benoit
Couturaud, Francis
Tromeur, Cécile
Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study
title Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study
title_full Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study
title_fullStr Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study
title_full_unstemmed Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study
title_short Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study
title_sort risk of venous thromboembolism in association with factor v leiden in cancer patients – the edith case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959061/
https://www.ncbi.nlm.nih.gov/pubmed/29775482
http://dx.doi.org/10.1371/journal.pone.0194973
work_keys_str_mv AT heraudeauadeline riskofvenousthromboembolisminassociationwithfactorvleidenincancerpatientstheedithcasecontrolstudy
AT dellucaurelien riskofvenousthromboembolisminassociationwithfactorvleidenincancerpatientstheedithcasecontrolstudy
AT lehenaffmickael riskofvenousthromboembolisminassociationwithfactorvleidenincancerpatientstheedithcasecontrolstudy
AT lacutkarine riskofvenousthromboembolisminassociationwithfactorvleidenincancerpatientstheedithcasecontrolstudy
AT leroyerchristophe riskofvenousthromboembolisminassociationwithfactorvleidenincancerpatientstheedithcasecontrolstudy
AT desruesbenoit riskofvenousthromboembolisminassociationwithfactorvleidenincancerpatientstheedithcasecontrolstudy
AT couturaudfrancis riskofvenousthromboembolisminassociationwithfactorvleidenincancerpatientstheedithcasecontrolstudy
AT tromeurcecile riskofvenousthromboembolisminassociationwithfactorvleidenincancerpatientstheedithcasecontrolstudy